Biotech

Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company more...

Initiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy Closed financing with net proceeds of $74.5 million Upcoming presentations more...

Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology . SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged more...

— Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis — — Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months — –Advancing newly discovered more...

DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference more...

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, more...

Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 PR Newswire SEATTLE and VANCOUVER, BC, Oct. 29, 2020 SEATTLE and VANCOUVER, BC , Oct. more...

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced today that, due to demand, the underwriter has more...

FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action – FENC PR Newswire NEW YORK, Oct. 28, 2020 NEW YORK , Oct. more...

LOS ANGELES, CA / ACCESSWIRE / October 28, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Fennec Pharmaceuticals Inc. (“Fennec” or “the Company”) more...